- Lobbying
- Lobbying by International Pharmaceutical Aerosol Consortium
Lobbying Relationship
Bills mentioned
S.2657: AGILE Act of 2019
Sponsor: Lisa Murkowski (R-Alaska)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Jeremy Scott | S. Asst./Intern Coord./L. Cor., Sen. Mike DeWine |
Maureen Hardwick | n/a |
Peter Blenkinsop | n/a |
Ballard Jamieson, Jr. | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Q1 Report
Q4 Report
Q3 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Amendment
Lobbying Issues
Agencies Lobbied
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Environmental Protection Agency (EPA)
Food & Drug Administration (FDA)
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Environmental Protection Agency (EPA)
Food & Drug Administration (FDA)
Type of Issue
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Lobbying Issues
Agencies Lobbied
Food & Drug Administration (FDA)
State - Dept of (DOS)
U.S. House of Representatives
U.S. Senate
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
Food & Drug Administration (FDA)
State - Dept of (DOS)
U.S. House of Representatives
U.S. Senate
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
Food & Drug Administration (FDA)
State - Dept of (DOS)
U.S. House of Representatives
U.S. Senate
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
Food & Drug Administration (FDA)
State - Dept of (DOS)
U.S. House of Representatives
U.S. Senate
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
Food & Drug Administration (FDA)
State - Dept of (DOS)
U.S. House of Representatives
U.S. Senate
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
Food & Drug Administration (FDA)
State - Dept of (DOS)
U.S. House of Representatives
U.S. Senate
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
Food & Drug Administration (FDA)
State - Dept of (DOS)
U.S. House of Representatives
U.S. Senate
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
Food & Drug Administration (FDA)
State - Dept of (DOS)
U.S. House of Representatives
U.S. Senate
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
Food & Drug Administration (FDA)
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
Food & Drug Administration (FDA)
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
Food & Drug Administration (FDA)
Type of Issue
Registration
Issue(s) they said they’d lobby about: United Nations Framework Convention on Climate Change
Montreal Protocol on Substances that Deplete the Ozone Layer.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate